Clinical Trials

For more information on any of the studies listed below, call (405) 271-7805 or email clinic@omrf.org.

Studies in which participants receive new (investigational) treatments:

Eli Lilly and Company, Protocol H9B-MC-BCDT. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE). (Currently Recruiting)

UCB Inc., Protocol No. SL0009. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Four 12‑week Treatment Cycles (48 weeks total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease EMBODY 1. (Currently Recruiting)

AstraZeneca, Protocol CD-IA-MEDI-545-1067. A Phase 2b, Dose-Ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus. (Currently Recruiting)

Dynavax Technologies Corporation, Protocol DV7-SLE-02. A Dose-Escalation, Multi-Center Study to Evaluate the Safety, Tolerability and Proof of Mechanism of DV1179 in Subjects with Systemic Lupus Erythematosus. (Currently Recruiting)

Rigel Pharmaceuticals, Inc.  Protocol C-932333-002. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of R333 6% Ointment Administered Topically to Discoid Lupus Erythematosus (DLE)and Systemic Lupus Erythematosus (SLE) Patients with Active Cutaneous Discoid Lesions. (Currently Recruiting)

Genentech, Protocol IFN4575g. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rontalizumab (rhuMAb IFNalpha) in Patients With Moderately to Severely Active Systemic Lupus Erythematosus. (Ongoing—Closed Recruitment)

Medimmune, Protocol MI-CP212A. Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects with Systemic Lupus Erythematosus or Myositis. (Ongoing—Closed Recruitment)

Anthera Pharmaceuticals, Inc. Protocol AN-SLE3322. An Open-label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) (Ongoing – Closed Recruitment)

Human Genome Sciences, Protocol Number HGS1006-C1066. A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-Bä),a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Protocol HGS1006-C1056 in the United States. (Ongoing – Closed Recruitment)

Human Genome Sciences, Protocol Number LBSL99. A Multi-Center, Open-Label, Continuation Trial of LymphoStat-Bä Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE) Who Completed the Phase 2 Protocol LBSL02 (Ongoing—Closed Recruitment)

Eli Lilly and Company, Protocol H9B-MC-BCDX. A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE). (Rollover Recruitment)

UCB Inc., Protocol  SL0012. A Phase 3, Multicenter, Open-Label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects EMBODY 4. (Rollover Recruitment)

Studies that involve blood drawing, medical history, physical examination, questionnaire completion and no changes to medications:

Bio-Rad Laboratories. Retrieval of anti-dsDNA antibodies for Diagnostic Test Development and Study of the Effects of Plasmapheresis on Inflammatory Markers in SLE. (Currently Recruiting)

SALMON PROMISSE: Predictors of Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS). (Currently Recruiting) 

SLICC: The Systemic Lupus International Collaborating Clinics Registry for Atherosclerosis, Neuropsychiatric Disorders and Cancer Risk in SLE.(Ongoing but closed to recruitment)

SLE/RA/APLS COHORTSOklahoma Cohort of Rheumatic Diseases (OCRD) — Formerly Oklahoma Lupus Cohort & Registry for the Antiphospholipid Syndrome & Oklahoma Rheumatoid Arthritis Cohort. (Currently Recruiting)

LCTC: A Prospective Registry to Study Presentation, Clinical Course, Treatment Patterns and Outcomes in Patients with Systemic Lupus Erythematosus. (ongoing but closed to recruitment)